Sugawara H, Kawakami M
Department of Integrated Medicine, Omiya Medical Center, Jichi Medical School.
Nihon Rinsho. 1999 Jul;57(7):1657-64.
Most users of synthetic-steroid hormones for postmenopausal hormone replacement or contraception, are healthy with a low background incidence of major diseases. Since they take these medicines for a long time, serious or frequent adverse effects should not be occurred. By changing content and reducing dose of both estrogen and progestagen, the incidences of venous and arterial thrombotic events by combined low dose oral contraceptives, is low in women who have not major risk factors. Although postmenopausal hormone replacement therapy decreases risk for coronary heart diseases, it seems to increases for venous thromboembolic events according to several clinical trials. In this article, the recent data on both the risk and the mechanisms of venous and arterial thrombotic events associated with use of oral contraceptives or with postmenopausal hormone replacement, is reviewed.
大多数使用合成类固醇激素进行绝经后激素替代或避孕的使用者身体健康,重大疾病的背景发病率较低。由于他们长期服用这些药物,不应出现严重或频繁的不良反应。通过改变雌激素和孕激素的含量并降低剂量,对于没有主要危险因素的女性,低剂量复方口服避孕药引起的静脉和动脉血栓形成事件的发生率较低。尽管绝经后激素替代疗法可降低冠心病风险,但根据几项临床试验,它似乎会增加静脉血栓栓塞事件的风险。在本文中,我们综述了与口服避孕药或绝经后激素替代相关的静脉和动脉血栓形成事件的风险及机制的最新数据。